The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events
Takashi Kawaguchi,Kanako Azuma,Motohiko Sano,Soan Kim,Yosuke Kawahara,Yoko Sano,Tomohide Shimodaira,Keiichiro Ishibashi,Tempei Miyaji,Ethan Basch,Takuhiro Yamaguchi +10 more
Reads0
Chats0
TLDR
There is underestimation in the assessment of adverse events in Japan, and that the Japanese version of the PRO-CTCAE had acceptable reliability and validity for common and clinically important symptoms.Abstract:
The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute as an adverse event assessment system to evaluate patients’ symptoms, which tend to be underestimated in cancer clinical trials. The aim of this study was to assess the psychometric properties of the Japanese version of the PRO-CTCAE and the degree of adverse event assessment discordance between clinicians and patients. A total of 187 cancer patients receiving systemic therapy were enrolled. Reproducibility, criterion validity, and responsiveness of the Japanese version of PROCTCAE were assessed. The EORTC QLQ-C30 was used as an external anchor. Discordance of assessment of adverse events between clinician and patients were also assessed using the CTCAE and PRO-CTCAE. A total of 187 participants (187 for criterion validity, 80 for reproducibility, and 100 for responsiveness), were analyzed (Mage = 62.4 years). All patients responded to at least one symptom item (M = 16). The mean (SD) intra-class correlation coefficients of overall reproducibility for the Japanese PRO-CTCAE was 0.63 (0.02). The correlation coefficient for the corresponding items in the EORTC QLQ-C30 and the Japanese PRO-CTCAE was high (Pearson r = 0.56–0.76). The analysis of responsiveness revealed significant dose-response trends (Jonckheere-Terpstra test, ps < 0.001). Depending on the adverse events, a discrepancy was observed in evaluation between the clinician and patient. These results revealed that there is underestimation in the assessment of adverse events in Japan, and that the Japanese version of the PRO-CTCAE had acceptable reliability and validity for common and clinically important symptoms.read more
Citations
More filters
Journal ArticleDOI
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics
Kelly S. Swanson,Glenn R. Gibson,Robert W. Hutkins,Raylene A. Reimer,Gregor Reid,Kristin Verbeke,Karen P. Scott,Hannah D. Holscher,Meghan B. Azad,Nathalie M. Delzenne,Mary Ellen Sanders +10 more
TL;DR: This Consensus Statement outlines the definition and scope of the term ‘synbiotics’ as determined by an expert panel convened by the International Scientific Association for Probiotics and Prebiotics in May 2019 and explores the levels of evidence, safety, effects upon targets and implications for stakeholders of the synbiotic concept.
Journal ArticleDOI
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Myriam Chalabi,Lorenzo F. Fanchi,Krijn K. Dijkstra,José G van den Berg,Arend G. J. Aalbers,Karolina Sikorska,Marta Lopez-Yurda,Cecile Grootscholten,Geerard L. Beets,Geerard L. Beets,Petur Snaebjornsson,Monique Maas,Marjolijn Mertz,Vivien Veninga,Gergana Bounova,Annegien Broeks,Regina G. H. Beets-Tan,Regina G. H. Beets-Tan,Thomas R de Wijkerslooth,Anja U. van Lent,Hendrik A Marsman,Elvira Nuijten,Niels F. M. Kok,Maria Kuiper,Wieke H M Verbeek,Marleen Kok,Monique E. van Leerdam,Ton N. Schumacher,Emile E. Voest,John B. A. G. Haanen +29 more
TL;DR: The data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data.
Journal ArticleDOI
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids,Andrew W. Roberts,Andrew W. Roberts,John F. Seymour,John F. Seymour,John M. Pagel,Brad S. Kahl,William G. Wierda,Soham D. Puvvada,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Ahmed Salem,Ahmed Salem,Martin Dunbar,Ming Zhu,Franklin Peale,Jeremy A. Ross,Lori A. Gressick,Monali Desai,Su Young Kim,Maria Verdugo,Rod A. Humerickhouse,Gary Gordon,John F. Gerecitano +24 more
TL;DR: Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes, and 1,200 mg was determined to be the recommended single- agent dose for future studies in FL and DLBCL.
Journal ArticleDOI
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens.
Journal ArticleDOI
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Mario A. Eisenberger,Anne-Claire Hardy-Bessard,Choung Soo Kim,Lajos Géczi,Daniel Ford,Loic Mourey,Joan Carles,Phillip Parente,Albert Font,Gabriel Kacso,Mustapha Chadjaa,Wenping Zhang,John Bernard,Johann S. de Bono +13 more
TL;DR: The efficacy of cabazitaxel in postdocetaxel patients with mCRPC was confirmed and the noninferiority end point was met; C20 maintained ≥ 50% of the OS benefit of C25 versus mitoxantrone in TROPIC.
References
More filters
Journal ArticleDOI
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken,Richard H. Creech,Douglass C. Tormey,John Horton,Thomas E. Davis,Eleanor T. McFadden,Paul P. Carbone +6 more
TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
Journal ArticleDOI
Guidelines, Criteria, and Rules of Thumb for Evaluating Normed and Standardized Assessment Instruments in Psychology.
TL;DR: In this paper, the authors provide guidelines, guidelines, and simple rules of thumb to assist the clinician faced with the challenge of choosing an appropriate test instrument for a given psychological assessment.
Journal ArticleDOI
Karnofsky performance status revisited: reliability, validity, and guidelines.
TL;DR: Oncologists may train themselves to use the Karnofsky Performance Status in a standard way, which should increase reliability and validity of the KPS and has implications for patients and research studies that use KPS as a stratifying variable.
Journal ArticleDOI
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Amylou C. Dueck,Tito R. Mendoza,Sandra A. Mitchell,Bryce B. Reeve,Kathleen Castro,Lauren J. Rogak,Thomas M. Atkinson,Antonia V. Bennett,Andrea Denicoff,Ann M. O'Mara,Yuelin Li,Steven B. Clauser,Donna M. Bryant,James D. Bearden,Theresa A. Gillis,Jay K. Harness,Robert D. Siegel,Diane Paul,Charles S. Cleeland,Deborah Schrag,Jeff A. Sloan,Amy P. Abernethy,Deborah Watkins Bruner,Lori M. Minasian,Ethan Basch,Ethan Basch +25 more
TL;DR: Evidence demonstrates favorable validity, reliability, and responsiveness in a large, heterogeneous US sample of patients undergoing cancer treatment in a patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Journal ArticleDOI
Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch,Ethan Basch,Bryce B. Reeve,Sandra A. Mitchell,Steven B. Clauser,Lori M. Minasian,Amylou C. Dueck,Tito R. Mendoza,Jennifer L. Hay,Thomas M. Atkinson,Amy P. Abernethy,Deborah Watkins Bruner,Charles S. Cleeland,Jeff A. Sloan,Ram Chilukuri,Paul Baumgartner,Andrea Denicoff,Diane St. Germain,Ann M. O'Mara,Alice P. Chen,Joseph Kelaghan,Antonia V. Bennett,Laura Sit,Lauren J. Rogak,Allison Barz,Diane Paul,Deborah Schrag +26 more
TL;DR: The Patient-reported outcome (PRO) CTCCAE (Pro-CTCAE) as mentioned in this paper was developed by a group of multidisciplinary investigators and patient representatives and provides an overview of qualitative and quantitative studies of its measurement properties.
Related Papers (5)
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Neil K. Aaronson,Sam H Ahmedzai,Bengt Bergman,Monika Bullinger,Ann Cull,Nicole Duez,Antonio Filiberti,Henning Flechtner,Stewart B. Fleishman,Johanna C. J. M. de Haes,Stein Kaasa,M. Klee,David Osoba,Darius Razavi,Peter B. Rofe,Simon Schraub,Kommer C. A. Sneeuw,Marianne Sullivan,Fumikazu Takeda +18 more